文献速递脑血管病

WATCHMAN装置左心耳封堵术与华法林或非维生素K拮抗剂口服抗凝药在非瓣膜性心房颤动二级预防中的成本效益比较

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
PubMed 文献 · Stroke · 2018-05-08

本研究基于非维生素K拮抗剂口服抗凝药和左心耳封堵术关键试验的二级预防亚组数据构建Markov模型,从美国Medicare支付方视角评估左心耳封堵术相比华法林、达比加群150 mg、阿哌沙班和利伐沙班在非瓣膜性心房颤动合并既往卒中或短暂性脑缺血发作患者中预防卒中的成本效益。结果显示,左心耳封堵术在第5年相对达比加群、第6年相对华法林和阿哌沙班达到成本效益,10年时质量调整生命年更高且总成本更低,成为优势策略。

要点

  • 左心耳封堵术在第5年相对达比加群、第6年相对华法林和阿哌沙班达到成本效益。
  • 10年时左心耳封堵术质量调整生命年更高且成本更低,为优势策略。
  • 左心耳封堵术在终生分析中保持优势策略地位。

核心结论

  • 左心耳封堵术 upfront 手术费用 initially 高于华法林和非维生素K拮抗剂口服抗凝药,但10年内提供更多质量调整生命年且总成本更低,是非瓣膜性心房颤动卒中二级预防中最具成本效益的治疗策略。

研究设计与样本

  • 构建Markov模型,使用非维生素K拮抗剂口服抗凝药和左心耳封堵术关键试验的二级预防亚组分析数据。
  • 成本来自2016年美国Medicare报销率和文献,从美国Medicare支付方视角进行终生(20年)horizon的成本效益分析。
  • 模型人群为10000例年龄70岁、CHA2DS2-VASc评分7分(年卒中风险=9.60%)、HAS-BLED评分3分(年出血风险=3.74%)的患者。

主要发现

  • 左心耳封堵术在第5年相对达比加群、第6年相对华法林和阿哌沙班达到成本效益。
  • 10年时,左心耳封堵术的质量调整生命年为4.986,华法林为4.769、达比加群为4.869、阿哌沙班为4.888、利伐沙班为4.810。
  • 10年时,左心耳封堵术的成本为$42 616,华法林为$53 770、达比加群为$58 774、阿哌沙班为$55 656、利伐沙班为$58 655。
  • 左心耳封堵术在终生分析中保持优势策略地位。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Once a patient with atrial fibrillation experiences an embolic event, the risk of a recurrent event increases 2.6-fold. New treatments have emerged as viable treatment alternatives to warfarin for stroke risk reduction in secondary prevention populations. This analysis sought to assess the cost-effectiveness of left atrial appendage closure (LAAC) compared with warfarin and the non-vitamin K antagonist oral anticoagulants dabigatran 150 mg, apixaban and rivaroxaban in the prevention of stroke in nonvalvular atrial fibrillation patients with a prior stroke or transient ischemic attack. METHODS: A Markov model was constructed using data from the secondary prevention subgroup analyses of the non-vitamin K antagonist oral anticoagulant and LAAC pivotal trials. Costs were from 2016 US Medicare reimbursement rates and the literature. The cost-effectiveness analysis was conducted from a US Medicare perspective over a lifetime (20 years) horizon. The model was populated with a cohort of 10 000 patients aged 70 years with a CHA2DS2-VASc score of 7 (annual stroke risk=9.60%) and HAS-BLED score of 3 (annual bleeding risk=3.74%). RESULTS: LAAC achieved cost-effectiveness relative to dabigatran at year 5 and warfarin and apixaban at year 6. At 10 years, LAAC had more quality-adjusted life years (4.986 versus 4.769, 4.869, 4.888, and 4.810) and lower costs ($42 616 versus $53 770, $58 774, $55 656, and $58 655) than warfarin, dabigatran, apixaban, and rivaroxaban, respectively, making LAAC the dominant (more effective and less costly) stroke risk reduction strategy. LAAC remained the dominant strategy over the lifetime analysis. CONCLUSIONS: Upfront procedure costs initially make LAAC higher cost than warfarin and the non-vitamin K antagonist oral anticoagulants, but within 10 years, LAAC delivers more quality-adjusted life years and has lower total costs, making LAAC the most cost-effective treatment strategy for secondary prevention of stroke in atrial fibrillation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Reddy VY, Akehurst RL, Amorosi SL, et al. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. Stroke. 2018. PMID: 29739915. doi:10.1161/STROKEAHA.117.018825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。